2020
DOI: 10.1080/20009666.2020.1766818
|View full text |Cite
|
Sign up to set email alerts
|

Sweet’s syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor

Abstract: Introduction: Gilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated acute myeloid leukemia (AML). We present a case of febrile neutropenia and neutrophilic dermatosis consistent with Sweet's syndrome (SS). Case history: A 55-year-old woman presented with fever and skin lesions after 4 weeks of initiation of Gilteritinib for AML. She was febrile, pancytopenic and neutropenic with absolute neutrophil count (ANC) of 0.1x10E3/UI. Examination revealed reddish and violaceous rashes on her extremities. Pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 13 publications
1
2
0
Order By: Relevance
“…FLT3 inhibitorinduced neutrophilic dermatoses have also been reported. [2][3][4] This confirmed the diagnosis of bullous Sweet syndrome, caused by midostaurin treatment. 5 In FLT3 inhibitor-induced neutrophilic dermatosis it has been hypothesized that terminal myeloid differentiation promotes AML blast to become mature neutrophils.…”
Section: Differential Diagnosis Included Skin Infection and Neutrophi...supporting
confidence: 70%
“…FLT3 inhibitorinduced neutrophilic dermatoses have also been reported. [2][3][4] This confirmed the diagnosis of bullous Sweet syndrome, caused by midostaurin treatment. 5 In FLT3 inhibitor-induced neutrophilic dermatosis it has been hypothesized that terminal myeloid differentiation promotes AML blast to become mature neutrophils.…”
Section: Differential Diagnosis Included Skin Infection and Neutrophi...supporting
confidence: 70%
“…Concerning myeloid neoplasm-associated NDs, there's mounting evidence that skin-infiltrating neutrophils may be clonally related to the neoplastic cells and may have differentiated from them [11], with some authors even suggesting that leukaemia cutis and Sweet syndrome (SS) associated with AML may be included in the same disease spectrum. Moreover, NDs, especially SS but also PG and neutrophilic eccrine hidradenitis, may be induced by drugs used to treat AML, in particular FLT3 inhibitors such as gilteritinib [2][3][4][5].…”
Section: Discussionmentioning
confidence: 99%
“…The dermal neutrophilic infiltrate favoured that diagnosis. FLT-3 inhibitors, such as gilterinib, which was reinitiated by the patient two weeks prior to this admission, have been associated with NDs [ 2 - 5 ]. We can hypothesise the contribution of this drug to the whole clinical picture, supporting the diagnosis of ND 2-4.…”
Section: Case Presentationmentioning
confidence: 99%
“…11 Another case report described Sweet syndrome in a 55-year-old female who presented with neutrophilic dermatosis after 4 weeks of gilteritinib therapy for AML. 12 The patient was started on prednisone but experienced flare with tapering. The gilteritinib was eventually stopped because of nonresponse and the drug's potential contribution to the Sweet syndrome flare.…”
Section: Sgba Plus Literature Review Of Gilteritinibmentioning
confidence: 99%
“…The patient died shortly afterward, secondary to disease progression and complications of sepsis. 12 The third included study aimed to investigate the clinical benefit of gilteritinib in the treatment of relapsed or refractory FLT3mutated AML in a randomized trial comparing gilteritinib with conventional salvage chemotherapy regimens, also known as the ADMIRAL trial. 13 In the ADMIRAL trial, females accounted for 53% of participants in the gilteritinib arm and 56.5% in the salvage chemotherapy arm.…”
Section: Sgba Plus Literature Review Of Gilteritinibmentioning
confidence: 99%